|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1994-4-13
|
|
pubmed:abstractText |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors are widely prescribed for hyperlipidemia, yet their effect on the evolution of coronary atherosclerosis has not been defined.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0009-7322
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
959-68
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8124836-Canada,
pubmed-meshheading:8124836-Cholesterol,
pubmed-meshheading:8124836-Coronary Angiography,
pubmed-meshheading:8124836-Coronary Artery Disease,
pubmed-meshheading:8124836-Double-Blind Method,
pubmed-meshheading:8124836-Female,
pubmed-meshheading:8124836-Follow-Up Studies,
pubmed-meshheading:8124836-Humans,
pubmed-meshheading:8124836-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:8124836-Lipids,
pubmed-meshheading:8124836-Lovastatin,
pubmed-meshheading:8124836-Male,
pubmed-meshheading:8124836-Middle Aged,
pubmed-meshheading:8124836-Multivariate Analysis,
pubmed-meshheading:8124836-Time Factors
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
|
|
pubmed:affiliation |
Division of Cardiology, Hartford Hospital, Conn 06115.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
